PTK2 and neoplasm: Interestingly, multiple previous studies have implicated FAK activation in the development of resistance against various chemotherapy agents through its regulation of the tumor microenvironment.[11, 15, 44] FAK signaling is hyperactivated by long‐term treatments that target KRAS vertical signaling components (e.g., RAF and EGFR).[45]